Literature DB >> 1562682

Clinical use of amphotericin B and derivatives: lore, mystique, and fact.

P D Hoeprich1.   

Abstract

Since 1955, when amphotericin B was introduced into clinical therapy, a lore has grown up surrounding its use that often lacks evidential basis. Matters such as rate of intravenous injection, periodicity of administration, dosage, and the monitoring of therapy should not be shrouded in a mystique that is passed on from one generation of house officers to another. Factual rationalization of the use of amphotericin B should be pursued and is attempted in this article.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1562682     DOI: 10.1093/clinids/14.supplement_1.s114

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  In vitro and in vivo experimental activities of antifungal agents against Fusarium solani.

Authors:  J Guarro; I Pujol; E Mayayo
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Lyophilized lecithin based oil-water microemulsions as a new and low toxic delivery system for amphotericin B.

Authors:  M A Moreno; P Frutos; M P Ballesteros
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

Review 3.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

4.  Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients.

Authors:  M Nucci; M Loureiro; F Silveira; A R Casali; L F Bouzas; E Velasco; N Spector; W Pulcheri
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis.

Authors:  J R Graybill; L K Najvar; A Fothergill; T Hardin; M Rinaldi; C Lambros; S L Regen
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

6.  Evidence for the formation of amphotericin B-phospholipid complexes in Langmuir monolayers.

Authors:  M R Lance; C Washington; S S Davis
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

7.  Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level.

Authors:  B Jahn; A Rampp; C Dick; A Jahn; M Palmer; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

Review 8.  Systemic Candida infections.

Authors:  L A Grohskopf; V T Andriole
Journal:  Yale J Biol Med       Date:  1996 Nov-Dec

Review 9.  Optimizing efficacy of amphotericin B through nanomodification.

Authors:  Suresh P Vyas; Swati Gupta
Journal:  Int J Nanomedicine       Date:  2006

10.  Antimicrobial-induced cognitive side effects.

Authors:  Amanda Warstler; Jennifer Bean
Journal:  Ment Health Clin       Date:  2016-06-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.